Tech Company Financing Transactions
Abcuro Funding Round
Abcuro, based in Newton, secured $200 million from New Enterprise Associates, Abrdn and Bain Capital Life Sciences.
Transaction Overview
Company Name
Announced On
2/13/2025
Transaction Type
Venture Equity
Amount
$200,000,000
Round
Series C
Investors
Proceeds Purpose
The company intends to use the funds to complete the registrational Phase 2/3 MUSCLE clinical trial evaluating ulviprubart (ABC008), a monoclonal antibody targeting killer cell lectin like receptor G1 (KLRG1), for the treatment of inclusion body myositis (IBM).
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
90 Bridge St. 100
Newton, MA 02458
USA
Newton, MA 02458
USA
Phone
Website
Email Address
Overview
We are developing first-in-class immunotherapies for autoimmune diseases and cancer through precise elimination or modulation of cytotoxic T and NK cells via KLRG1. We believe this strategy will result in therapeutics with reduced toxicity compared to existing therapeutic approaches for T cell modulation.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chairman
Steven Greenberg
Chief Executive Officer
David de Graaf
Chief Financial Officer
David Neafus
Chief Medical Officer
Richard Polisson
Chief Operating Officer
Evan Thompson
Chief Scientific Officer
Stefano Gulla
Browse more venture capital transactions:
Prev: 2/13/2025: fal - features and labels venture capital transaction
Next: 2/13/2025: Newleos Therapeutics venture capital transaction
Share this article
About Our VC Transactions Data
Our team works diligently to report on all VC transactions involving tech companies. All VC database entries reported here come from company press releases and news coverage. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs